ArticleRheumatology international2026
Suboptimal contraceptive counseling and use in women with autoimmune rheumatic diseases of childbearing age: findings from a cross-sectional survey of patients.
Article in Rheumatology international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Fertility and Birth Outcomes in Rheumatoid Arthritis: A Narrative Review.Rheumatology and therapy · 2026Review
- Patient-reported reproductive concerns and care needs among women with systemic lupus erythematosus: a descriptive qualitative study using patient journey mapping.Rheumatology international · 2026Article
- Reproductive health awareness and family planning practices among women with systemic autoimmune diseases: survey based study.Rheumatology international · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Women with autoimmune rheumatic diseases (ARDs) require effective contraception to prevent unplanned pregnancies and minimize risks associated with disease activity and teratogenic medications. Despite established guidelines, contraception counseling and use remain suboptimal. This study aimed to assess contraception use and patient preferences for reproductive health counseling in a cohort of women with ARDs. We conducted a cross-sectional survey between January 2023 and February 2024 at a tertiary rheumatology center in Italy. Consecutive women aged 18-50 years with a confirmed autoimmune rheumatic disease (ARD) diagnosis were invited to complete a 47-item anonymous questionnaire covering sexuality, contraception, fertility, pregnancy, breastfeeding, medication safety, and disease transmissibility. Descriptive statistics and subgroup comparisons were performed using chi-square, Fisher's exact test, and Mann-Whitney U test, with significance set at p < 0.05. A total of 189 women participated, of whom 156 were premenopausal (mean age 31 years, mean disease duration 7 years). Among them, 37.8% (n = 59) reported not using any contraception, 40.4% (n = 63) used barrier methods, and 23.1% (n = 36) relied on effective or highly effective methods, including only 5.8% (n = 9) using long-acting reversible contraceptives. Alarmingly, 71.0% of women treated with teratogenic drugs were not using contraception. While 64.7% (n = 101) had discussed contraception with their partner, only 13.5% (n = 21) had spoken with a healthcare provider, and merely 6.3% (n = 2) of those on teratogenic medications expressed interest in dedicated counseling. Our findings highlight significant gaps in contraception counseling and adherence among women with ARDs, particularly those at high risk for medication-related fetal harm. Given the potential impact on maternal-fetal health, rheumatologists should routinely integrate reproductive health discussions into patient care and collaborate with gynecologists to improve contraception uptake. Targeted educational programs may enhance awareness and adherence to contraception guidelines, ultimately optimizing pregnancy outcomes in women with ARDs.
Indexed as
Identifiers
41642351What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.